Trials / Completed
CompletedNCT01922128
Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration
A Phase 1 Randomized, Double-masked, Vehicle-controlled, Dose Escalation Study of the Ocular Safety and Tolerability of MC-1101 in Medically Stable Individuals
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- MacuCLEAR, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
Study to evaluate the safety and tolerability of MC-1101, a potential topical treatment for non-edxudative age Related Macular Degeneration (AMD) in medically stable individuals.
Detailed description
MC-1101 is a topical version of a previously approved anti-hypertensive drug that is intended to increase choroidal blood flow. * A reduction of choroidal blood flow has been identified in patients with AMD * This study will evaluate 0.5% and 1.0% potencies of MC-1101 delivered 2X per day.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MC-1101, Placebo | One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2013-11-01
- Completion
- 2013-12-01
- First posted
- 2013-08-14
- Last updated
- 2014-04-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01922128. Inclusion in this directory is not an endorsement.